Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Baker

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Clinical Pharmacology and Therapeutics|February 20, 2013
Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitorsC D Drenberg, S D Baker, A Sparreboom
Journal of the National Cancer Institute|March 1, 1995
Should anticancer drug doses be adjusted in the obese patient?S D Baker, L B Grochow, R C Donehower
Experimental Cell Research|June 25, 1998
Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopyR M Wadkins, M K Danks, L Horowitz, et al.
Leukemia|October 25, 2016
E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemiaI-K Park, W Blum, S D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatinE K Rowinsky, M Jiroutek, P Bonomi, et al.
British Journal of Cancer|July 14, 2017
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlationsS Hu, R H J Mathijssen, P de Bruijn, et al.
Clinical Pharmacology and Therapeutics|May 30, 2008
Influence of solute carriers on the pharmacokinetics of CYP3A4 probesR M Franke, S D Baker, R H Mathijssen, et al.
British Journal of Cancer|January 9, 2014
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlationsS Hu, R H J Mathijssen, P de Bruijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Population pharmacokinetic model for topotecan derived from phase I clinical trialsJ M Gallo, P B Laub, E K Rowinsky, et al.
Cytometry|February 1, 1995
Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopyS D Baker, R M Wadkins, C F Stewart, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|February 20, 2013
Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitorsC D Drenberg, S D Baker, A Sparreboom
Journal of the National Cancer Institute|March 1, 1995
Should anticancer drug doses be adjusted in the obese patient?S D Baker, L B Grochow, R C Donehower
Experimental Cell Research|June 25, 1998
Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopyR M Wadkins, M K Danks, L Horowitz, et al.
Leukemia|October 25, 2016
E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemiaI-K Park, W Blum, S D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatinE K Rowinsky, M Jiroutek, P Bonomi, et al.
British Journal of Cancer|July 14, 2017
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlationsS Hu, R H J Mathijssen, P de Bruijn, et al.
Clinical Pharmacology and Therapeutics|May 30, 2008
Influence of solute carriers on the pharmacokinetics of CYP3A4 probesR M Franke, S D Baker, R H Mathijssen, et al.
British Journal of Cancer|January 9, 2014
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlationsS Hu, R H J Mathijssen, P de Bruijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Population pharmacokinetic model for topotecan derived from phase I clinical trialsJ M Gallo, P B Laub, E K Rowinsky, et al.
Cytometry|February 1, 1995
Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopyS D Baker, R M Wadkins, C F Stewart, et al.
Pageof 7